Limb-Girdle Muscular Dystrophy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Limb-Girdle Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions.
Limb-girdle muscular dystrophy encompasses a spectrum of disorders impacting the voluntary muscles encircling the hips and shoulders, exhibiting equal prevalence in males and females. The majority of these dystrophies follow an autosomal recessive inheritance pattern, although some rarer forms adhere to an autosomal dominant model. With over 20 recognized types, this condition arises from genetic material (DNA) alterations and can manifest at any point in life. Its characteristic feature is progressive muscle weakness, affecting daily activities. Diagnosis involves genetic testing, clinical evaluation, and may require interventions to manage symptoms and enhance quality of life, given the absence of a cure.
The Limb-Girdle Muscular Dystrophy drugs in development market research report provide comprehensive information on the therapeutics under development for Limb-Girdle Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Limb-Girdle Muscular Dystrophy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Limb-Girdle Muscular Dystrophy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 22 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Limb-Girdle Muscular Dystrophy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Limb-Girdle Muscular Dystrophy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Limb-Girdle Muscular Dystrophy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Antisense Therapeutics LtdAsklepios BioPharmaceutical Inc
Atamyo Therapeutics SAS
Constant Therapeutics LLC
DR.Noah Biotech Inc
Edgewise Therapeutics Inc
Kantify
ML Bio Solutions Inc
MyoPax GmbH
Nationwide Children's Hospital
Recursion Pharmaceuticals Inc
Santhera Pharmaceuticals Holding AG
Sarcomed AB
Sarepta Therapeutics Inc
Vita Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Limb-Girdle Muscular Dystrophy reports